drug development

R&D

Solving the hit-to-lead selection challenge for novel target...

The drug target universe is expanding to include RNA and protein-protein interactions, but poor-quality data is holding back progress.

Oncology

Partner Content

8th Tumor Models San Francisco Summit 2024

Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the fie

R&D

Partner Content

7th Obesity & NASH Drug Development Summit

Reuniting metabolic experts to enable the assessment of the competitive landscape, the 7th Obesity & NASH Drug Development Summit is your exclusive industry meeting to:

R&D

Partner Content

Antifibrotic Drug Development Summit

As fibrosis stakeholders invest in bolstering their early pipeline to limit early candidate drop off, the 7th Antifibrotic Drug Development (AFDD) Summit explores actionable strategies to t

R&D

Partner Content

Champion Innovation at the 7th Dermatology Drug Development ...

Following 6 FDA approvals of JAK inhibitors and the breakthroughs of the first approved therapies in Prurigo Nodularis, Alopecia Areata and a gene therapy for Dystrophic Epidermolysis Bullo

R&D